

PHARMACY GNIPST BULLETIN

Volume-4, Issue-4



**GURU NANAK INSTITUTE OF PHARMACEUTICAL
SCIENCE AND TECHNOLOGY**

157/F, Nilgunj Road, Kolkata- 700114, West Bengal, India

Contents

01 Message from Director and Principal

02 Recent Researches

03 New Drug Approvals

04 Clinical Trial News

05 Disease Outbreak News

06 Campus News

07 Special Page and Game time





MESSAGE FROM HONORABLE DIRECTOR

As the Director of Guru Nanak Institute of Pharmaceutical Science and Technology, I extend my heartfelt greetings and warm wishes to all our students, faculty members, staff, alumni, and well-wishers on the joyous occasion of **Subho Nababarsho**.

The Bengali New Year marks a time of renewal, hope, and fresh beginnings. It is a celebration of our rich cultural heritage, traditions, and the spirit of togetherness. This auspicious occasion inspires us to embrace new opportunities, set higher goals, and move forward with positivity and determination.

At GNIPST, we are committed not only to academic excellence but also to fostering cultural values, unity, and holistic development among our students. Festivals like Nababarsho remind us of the importance of harmony, respect, and collective growth in building a vibrant and progressive community. On this special day, let us welcome the New Year with enthusiasm, optimism, and a renewed commitment to excellence in all our endeavors. May this year bring success, good health, happiness, and prosperity to each one of you.

Wishing you all a very Happy, Prosperous, and Joyful **Subho Nababarsho!**

Prof. (Dr.) Abhijit Sengupta

MESSAGE FROM HONORABLE PRINCIPAL

I extend my warm greetings and heartfelt best wishes to our students, faculty members, staff, alumni, and valued partners on the joyous and auspicious occasion of Subho Nababarsho.

The Bengali New Year is a celebration of joy, unity, and positivity. It marks a time of renewal, harmony, and the strengthening of bonds that bring us together as a vibrant and inclusive community.

At Guru Nanak Institute of Pharmaceutical Science and Technology (GNIPST), we believe that education goes beyond academics to embrace cultural values, social harmony, and holistic development. Since our inception in 2005, GNIPST has grown into a distinguished centre of pharmaceutical education, recognized by the Pharmacy Council of India (PCI), accredited by NAAC and NBA, and ranked 85th in NIRF 2025. Our commitment remains steadfast in nurturing responsible professionals who uphold the values of integrity, collaboration, and respect.

On this festive occasion, let us reaffirm our dedication to fostering unity, positivity, and mutual respect within our academic community. May the spirit of the New Year inspire creativity, enthusiasm, and a renewed drive to achieve excellence in all our endeavors.

Let us celebrate responsibly, spreading happiness while being mindful of safety and environmental sustainability.

Wishing you all a joyful, prosperous, and fulfilling Subho Nababarsho!

Prof. (Dr.) Lopamudra Datta





RECENT RESEARCHES



WHO's head of emergencies reaffirms support to Lebanon's health system amid escalating needs

MORE INFO

www.who.int/

Lebanon's health system continues to function despite the mounting pressures of conflict, displacement and repeated attacks on health care – but without urgent action and sustained international support, access to essential health services is increasingly at risk.

Dr Chikwe Ihekweazu, Executive Director of WHO's Health Emergencies Programme, has concluded a three-day visit to Lebanon, reaffirming WHO's support for the national health emergency response. "I was deeply moved by the resilience of the displaced families I met, and by the unwavering commitment of frontline workers and partners, including WHO colleagues," said Dr Ihekweazu. "Their dedication, combined with investments in preparedness, have kept the health system functioning for now, but it is unclear how long it can withstand the repeated shocks as the conflict continues."

Conflict deepens health crisis across Middle East, WHO says

MORE INFO

www.who.int/

More than ten days into the latest escalation of conflict in the Middle East, health systems across the Region are coming under strain as injuries and displacement rise, attacks on health care continue, and public health risks increase.

National health authorities in Iran report more than 1300 deaths and 9000 injuries, and in Lebanon report at least 570 deaths and more than 1400 injuries. In Israel, authorities report 15 deaths and 2142 injuries. Temporary airspace restrictions have disrupted the movement of medical supplies from WHO's global logistics hub in Dubai. More than 50 emergency supply requests, intended to benefit over 1.5 million people across 25 countries, are affected, resulting in significant backlogs. Current priority shipments include supplies planned for Al Arish, Egypt, to support the Gaza response, as well as Lebanon and Afghanistan. The first shipment, containing cholera response supplies for Mozambique, is expected to depart from the hub in the coming week.

The role of the health sector in supporting parents and their caregiving potential

MORE INFO

www.who.int/

Parents and caregivers play a pivotal role in shaping the health, development and well-being of children across the life course. But they cannot do it alone. All parents need some support. Supporting parents and caregivers requires a whole-of-society approach, with coordinated responses from the health, education, social services, private and other sectors.

This webinar will explore how the health sector can better support parents and caregivers — from pregnancy through childhood and adolescence — by integrating evidence-based support into routine health services, strengthening health workers' practices, and fostering coordinated care within and across sectors.



FDA

NEW DRUG APPROVALS

Lifyorli (relacorilant) Capsules

- Date of Approval: March 25, 2026
- Company: Concept Therapeutics Incorporated
- Treatment for: Ovarian Cancer



Avlayah (tvidenofusp alfa-eknm) Lyophilized Powder for Injection

- Date of Approval: March 24, 2026
- Company: Denali Therapeutics Inc.
- Treatment for: Mucopolysaccharidosis Type II



Awiaqi (insulin icodec-abae) Injection

- Date of Approval: March 26, 2026
- Company: Novo Nordisk
- Treatment for: Type 2 Diabetes



Kresladi (marnetegrage autotemcel) Suspension for Intravenous Infusion

- Date of Approval: March 26, 2026
- Company: Rocket Pharmaceuticals, Inc.
- Treatment for: Leukocyte Adhesion Deficiency-I



Ponlimsi (denosumab-adet) Injection

- Date of Approval: March 27, 2026
- Company: Teva Pharmaceutical Industries Ltd.
- Treatment for: Osteoporosis



Foundayo (orforglipron) Tablets

- Date of Approval: April 1, 2026
- Company: Eli Lilly and Company
- Treatment for: Weight Loss



Idvynso (doravirine and islatravir) Tablets

- Date of Approval: April 20, 2026
- Company: Merck
- Treatment for: HIV Infection



<https://www.drugs.com/newdrugs-archive/2025.html>



CLINICAL TRIAL NEWS



01.

FORE Biotherapeutics Receives Breakthrough Therapy Designation for Plixorafenib

PHILADELPHIA--(BUSINESS WIRE) April 1, 2026 --FORE Biotherapeutics, a registration stage company dedicated to developing targeted therapies to treat patients with cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to plixorafenib for the treatment of adult patients with BRAF V600E-mutated high-grade glioma (HGG).

02.

Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer

PHILADELPHIA, April 02, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors, today announced that the U.S. Food and Drug Administration ("FDA") has granted Fast Track Designation to CTIM-76, a CLDN6 x CD3 T cell engaging bispecific antibody, for the treatment of platinum-resistant ovarian cancer ("PROC") in patients that have received all standard of care therapies.

03.

Amgen Announces Positive Topline Phase 3 Results for Subcutaneous Tepezza in Adults Living With Moderate-to-Severe Active Thyroid Eye Disease

THOUSAND OAKS, Calif., April 6, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced positive topline results from a Phase 3 trial of Tepezza (teprotumumab-trbw) administered by subcutaneous injection via an on-body injector (OBI) in participants with moderate-to-severe active Thyroid Eye Disease (TED).

04.

Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli (relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Apr. 10, 2026-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today presented final overall survival data from its pivotal Phase 3 ROSELLA trial of Lifyorli™ (relacorilant)

05.

GSK Presents Positive Data for B7-H4-Targeted ADC Mocertatug Rezetecan in Gynecological Cancers

Philadelphia, PA, April 12 2026 -- GSK plc (LSE/NYSE: GSK) today announced positive findings from its global phase I BEHOLD-1 clinical trial for mocertatug rezetecan (or Mo-Rez for short), a novel antibody-drug conjugate (ADC) targeting the B7-H4 antigen. At the highest doses evaluated, Mo-Rez monotherapy achieved confirmed objective response rates (cORR) of 62% (5.8 mg/kg n=21/34; 95% CI: 44, 78) in platinum-resistant ovarian cancer (PROC) and 67% (4.8 mg/kg n=8/12; 95% CI: 35, 90) in recurrent or advanced endometrial cancer (EC).¹

06.

Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer

REDWOOD CITY, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced positive topline results from its global, randomized, controlled Phase 3 RASolute 302 clinical trial evaluating daraxonrasib in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who had been previously treated. Daraxonrasib taken orally once daily demonstrated statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) compared with standard of care cytotoxic chemotherapy delivered intravenously.

07.

Update on FDA Advisory Committee Vote on Camizestrant in Combination with a CDK4/6 Inhibitor for Advanced HR-Positive Breast Cancer

30 April 2026 -- The US Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) did not reach a majority vote in favor of the benefit risk profile of AstraZeneca's camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) for the 1st-line treatment of patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer whose tumours have an emergent ESR1 mutation, based on the SERENA-6 Phase III trial. The Committee voted 3 to 6.

MORE INFORMATION ➔

https://www.drugs.com/clinical_trials/praxis-precision-medicines-announces-fda-has-granted-breakthrough-therapy-designation-22271.html






DISEASE OUTBREAK NEWS (DONS)

Avian Influenza A(H9N2) - Italy

10 April 2026

Situation at a glance

On 21 March 2026, the National International Health Regulations (IHR) Focal Point for Italy notified the World Health Organization (WHO) of the identification of a human case of avian influenza A(H9) in an adult male returning from Senegal. Next generation sequencing confirmed Influenza A(H9N2). According to epidemiological investigations, the patient had no known history of exposure to poultry or any person with similar symptoms prior to the onset of symptoms. Authorities in Italy have implemented a series of measures aimed at monitoring, preventing and controlling the situation. According to the IHR (2005), a human infection caused by a novel influenza A virus subtype is an event that has the potential for high public health impact and must be notified to the WHO. This is the first imported human case of avian Influenza A(H9N2) reported in the European Region. Based on currently available information, WHO assesses the current risk to the general population posed by A(H9N2) viruses as low but continues to monitor these viruses and the situation globally.



MORE INFO <https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON595>

Measles - Bangladesh

23 April 2026

Situation at a glance


On 4 April 2026, the National International Health Regulations (IHR) Focal Point for Bangladesh notified WHO of a nationwide increase in measles cases, geographically affecting 58 out of 64 districts across all eight divisions in Bangladesh. A total of 19 161 suspected measles cases and 2897 laboratory-confirmed measles cases have been reported between 15 March and 14 April 2026, including 166 measles related deaths (CFR 0.9%). The majority (79%) of the reported cases are children aged under 5 years. A targeted measles-rubella (MR) vaccination campaign started on 5 April, and various outbreak response measures are ongoing including strengthening nationwide surveillance and epidemiological analysis to enhance case detection and reporting. Based on currently available information, WHO assesses the risk at the national level as high due to ongoing transmission across multiple divisions, the large number of susceptible children, documented immunity gaps, and the occurrence of suspected measles-related deaths.



MORE INFO <https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON596>




CAMPUS NEWS



1. **Success Story:** The Heartiest congratulations to our students DEBJIT DHAR, RAHUL KHATA have been successfully placed at Fresenius Kabi India Pvt. Ltd. in Sales Trainee . His dedication, hard work, and perseverance have truly paid off. GNIPST is very proud to see you achieve this milestone and wish you great success in your professional journey ahead.



2. **Success Story:** The Heartiest congratulations to our students Aratrika Kansabanik, Nafisha Shafkat & MRIDUL KUMAR BEJ have been successfully placed at Emami Frank Ross as Pharmacist . His dedication, hard work, and perseverance have truly paid off. GNIPST is very proud to see you achieve this milestone and wish you great success in your professional journey ahead.



3. **Success Story:** The Heartiest congratulations to our students Megha Roy and Supriti Das have been successfully selected for the position of “Pharmacist” in West Bengal Health & Family Welfare. His dedication, hard work, and perseverance have truly paid off. GNIPST is very proud to see you achieve this milestone and wish you great success in your professional journey ahead.



www.gnipst.ac.in




Poila Baishakh: Celebrating the Bengali New Year with Tradition and Hope

Poila Baishakh, observed on 15th April, marks the beginning of the Bengali New Year and stands as one of the most deeply loved cultural festivals across Bengal. The term "Poila Baishakh" simply means the first day of the month of Baishakh in the Bengali calendar. People welcome the occasion with fresh clothes, traditional foods, cultural programs, music, and the warmth of family gatherings. Homes and shops are scrubbed clean and lovingly decorated, while businessmen open new accounting ledgers through the cherished ritual of Haal Khata, embracing prosperity and the promise of fresh beginnings. Temples and community spaces fill with prayers for peace, success, and happiness in the year ahead. The festival beautifully captures Bengali heritage, togetherness, and the enduring spirit of artistic tradition.

The true significance of Poila Baishakh lies in its quiet message of renewal, harmony, and cultural belonging. It gently urges people to leave behind past sorrows and step into the new year with open hearts and quiet optimism. The festival deepens social bonds by drawing families, friends, and communities closer, cutting across lines of religion and social background. Beloved songs like "Esho He Boishakh" and colourful folk fairs breathe life into the celebrations while keeping Bengal's rich cultural legacy alive and breathing. Poila Baishakh is not merely a marking of time or tradition — it is a living reminder of the values of unity, gratitude, and the enduring human hope for a brighter, more prosperous future.



GNIPST GAME TIME



Guess the Generic Name

1. Brand Name: Crocin
2. Brand Name: Augmentin
3. Brand Name: Pantocid
4. Brand Name: Glycomet
5. Brand Name: Allegra
6. Brand Name: Azee
7. Brand Name: Ecosprin
8. Brand Name: Telma
9. Brand Name: Shelcal
10. Brand Name: Montek-LC



Stay tuned for to the next edition for a shout out to fastest correct answers!

Submit your answer



SCAN
ME

or

CLICK
HERE

Celebrating the Achievers!



Suman Bhattacharjee
B. Pharm, 8th Semester

Guru Nanak Institute of Pharmaceutical Science and Technology



Editorial Board

Editor-in-Chief

Prof. (Dr.) Abhijit Sengupta

Managing Editors

Prof. (Dr.) Lopamudra Datta

Associate Editors

Mr. Tushar Adhikari

Ms. Manjarima Ganguli

Editorial Board Members

Mrs. Indrani Banerjee Chakraborty

Ms. Parnasree Chakraborty

Ms. Lopamudra Saha

Mr. Sarthak Saha



COURSES OFFERED

PHARMACY UG COURSES

- Bachelor of Pharmacy (B.Pharm)

PHARMACY DIPLOMA COURSES

- Diploma in Pharmacy (D.Pharm)

PHARMACY PG COURSES

- M.Pharm in Pharmaceutics
- M.Pharm in Pharmacology
- M.Pharm in Pharmaceutical Chemistry
- M.Pharm in Quality assurance
- M.Pharm in Regulatory Affairs
- M.Pharm in Pharmacognosy
- M.Pharm in Pharmaceutical Biotechnology

Major Recruiters



Latest news



www.gnipst.ac.in



www.facebook.com



www.linkedin.com



api.whatsapp.com



GNIPST BULLETIN 2026

